CHRODIS Criteria Applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in Allergic Rhinitis: a SUNFRAIL Report

Overview

Journal Clin Transl Allergy

Publisher Wiley

Specialty Allergy & Immunology

Date 2017 Oct 28

PMID 29075437

Citations 17

Authors

J Bousquet

G L Onorato

C Bachert

M Barbolini

A Bedbrook

L Bjermer

J Correia de Sousa

N H Chavannes

A A Cruz

E De Manuel Keenoy

P Devillier

J Fonseca

S Hun

T Kostka

P W Hellings

M Illario

J C Ivancevich

D Larenas-Linnemann

J Millot-Keurinck

D Ryan

B Samolinski

A Sheikh

A Yorgancioglu

I Agache

S Arnavielhe

M Bewick

I Annesi-Maesano

J M Anto

K C Bergmann

C Bindslev-Jensen

S Bosnic-Anticevich

J Bouchard

D P Caimmi

P Camargos

G W Canonica

V Cardona

A M Carriazo

C Cingi

E Colgan

A Custovic

R Dahl

P Demoly

G de Vries

W J Fokkens

J F Fontaine

B Gemicioglu

N Guldemond

Z Gutter

T Haahtela

B Hellqvist-Dahl

E Jares

G Joos

J Just

N Khaltaev

T Keil

L Klimek

M L Kowalski

I Kull

P Kuna

V Kvedariene

D Laune

R Louis

A Magnan

J Malva

E Mathieu-Dupas

E Melen

E Menditto

M Morais-Almeida

R Mosges

J Mullol

R Murray

H Neffen

R OHehir

S Palkonen

N G Papadopoulos

G Passalacqua

J L Pepin

F Portejoie

D Price

B Pugin

F Raciborski

F E R Simons

M Sova

O Spranger

C Stellato

A Todo Bom

P V Tomazic

M Triggiani

A Valero

E Valovirta

O Vandenplas

A Valiulis

M van Eerd

M T Ventura

M Wickman

I Young

T Zuberbier

A Zurkuhlen

A Senn

Affiliations

Soon will be listed here.

Abstract

A Good Practice is a practice that works well, produces good results, and is recommended as a model. MACVIA-ARIA Sentinel Network (MASK), the new Allergic Rhinitis and its Impact on Asthma (ARIA) initiative, is an example of a Good Practice focusing on the implementation of multi-sectoral care pathways using emerging technologies with real life data in rhinitis and asthma multi-morbidity. The European Union Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS) has developed a checklist of 28 items for the evaluation of Good Practices. SUNFRAIL (Reference Sites Network for Prevention and Care of Frailty and Chronic Conditions in community dwelling persons of EU Countries), a European Union project, assessed whether MASK is in line with the 28 items of JA-CHRODIS. A short summary was proposed for each item and 18 experts, all members of ARIA and SUNFRAIL from 12 countries, assessed the 28 items using a Survey Monkey-based questionnaire. A visual analogue scale (VAS) from 0 (strongly disagree) to 100 (strongly agree) was used. Agreement equal or over 75% was observed for 14 items (50%). MASK is following the JA-CHRODIS recommendations for the evaluation of Good Practices.

Citing Articles

Real-life evidence in allergen immunotherapy: Moving forward with mHealth apps.

Sousa-Pinto B, Pfaar O, Bousquet J Allergol Select. 2023; 7:47-56.

PMID: 36925994 PMC: 10012883. DOI: 10.5414/ALX02343E.

Digitally-enabled, patient-centred care in rhinitis and asthma multimorbidity: The ARIA-MASK-air approach.

Bousquet J, Anto J, Sousa-Pinto B, Czarlewski W, Bedbrook A, Haahtela T Clin Transl Allergy. 2023; 13(1):e12215.

PMID: 36705508 PMC: 9823305. DOI: 10.1002/clt2.12215.

Real-world data using mHealth apps in rhinitis, rhinosinusitis and their multimorbidities.

Sousa-Pinto B, Anto A, Berger M, Dramburg S, Pfaar O, Klimek L Clin Transl Allergy. 2022; 12(11):e12208.

PMID: 36434742 PMC: 9673175. DOI: 10.1002/clt2.12208.

ARIA 2019 Care Pathways for Allergic Rhinitis in the Kuwait Health Care System.

Al-Ahmad M, Nurkic J, Bachert C, Pfaar O, Schunemann H, Czarlewski W Med Princ Pract. 2020; 30(4):320-330.

PMID: 33099546 PMC: 8436665. DOI: 10.1159/000512493.

Aligning the Good Practice MASK With the Objectives of the European Innovation Partnership on Active and Healthy Ageing.

Bousquet J, Farrell J, Illario M Allergy Asthma Immunol Res. 2020; 12(2):238-258.

PMID: 32009320 PMC: 6997284. DOI: 10.4168/aair.2020.12.2.238.

References

Bousquet J, Schunemann H, Bousquet P, Bachert C, Canonica G, Casale T . How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement. Allergy. 2011; 66(6):765-74. DOI: 10.1111/j.1398-9995.2011.02590.x. View

Smith A, Pitt A, Rodruiguez A, Alio J, Marti N, Teus M . The economic and quality of life impact of seasonal allergic conjunctivitis in a Spanish setting. Ophthalmic Epidemiol. 2005; 12(4):233-42. DOI: 10.1080/09286580590967781. View

Bousquet J, Neukirch F, Bousquet P, Gehano P, Klossek J, Le Gal M . Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol. 2006; 117(1):158-62. DOI: 10.1016/j.jaci.2005.09.047. View

Bousquet J, Agache I, Anto J, Bergmann K, Bachert C, Annesi-Maesano I . Google Trends terms reporting rhinitis and related topics differ in European countries. Allergy. 2017; 72(8):1261-1266. DOI: 10.1111/all.13137. View

Meltzer E, Farrar J, Sennett C . Findings from an Online Survey Assessing the Burden and Management of Seasonal Allergic Rhinoconjunctivitis in US Patients. J Allergy Clin Immunol Pract. 2016; 5(3):779-789.e6. DOI: 10.1016/j.jaip.2016.10.010. View

Bousquet J, Hellings P, Agache I, Bedbrook A, Bachert C, Bergmann K . ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clin Transl Allergy. 2017; 6:47. PMC: 5203711. DOI: 10.1186/s13601-016-0137-4. View

Marcellusi A, Viti R, Incorvaia C, Mennini F . [Direct and indirect costs associated with respiratory allergic diseases in Italy. A probabilistic cost of illness study]. Recenti Prog Med. 2015; 106(10):517-27. DOI: 10.1701/2032.22086. View

Calderon M, Demoly P, Casale T, Akdis C, Bachert C, Bewick M . Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy.... Clin Transl Allergy. 2016; 6:41. PMC: 5120439. DOI: 10.1186/s13601-016-0131-x. View

Bousquet J, Annesi-Maesano I, Carat F, Leger D, Rugina M, Pribil C . Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy. 2005; 35(6):728-32. DOI: 10.1111/j.1365-2222.2005.02274.x. View

10.

Carlsen K, Haahtela T, Carlsen K, Smith A, Bjerke M, Wickman M . Integrated Allergy and Asthma Prevention and Care: Report of the MeDALL/AIRWAYS ICPs Meeting at the Ministry of Health and Care Services, Oslo, Norway. Int Arch Allergy Immunol. 2015; 167(1):57-64. DOI: 10.1159/000431359. View

11.

Klimek L, Bergmann K, Biedermann T, Bousquet J, Hellings P, Jung K . Visual analogue scales (VAS): Measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: Position Paper of the German Society of Allergology (AeDA) and the German Society of.... Allergo J Int. 2017; 26(1):16-24. PMC: 5288410. DOI: 10.1007/s40629-016-0006-7. View

12.

Hellings P, Fokkens W, Bachert C, Akdis C, Bieber T, Agache I . Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. Allergy. 2017; 72(9):1297-1305. DOI: 10.1111/all.13162. View

13.

de la Hoz Caballer B, Rodriguez M, Fraj J, Cerecedo I, Antolin-Amerigo D, Colas C . Allergic rhinitis and its impact on work productivity in primary care practice and a comparison with other common diseases: the Cross-sectional study to evAluate work Productivity in allergic Rhinitis compared with other common dIseases (CAPRI) study. Am J Rhinol Allergy. 2012; 26(5):390-4. PMC: 3904041. DOI: 10.2500/ajra.2012.26.3799. View

14.

Bousquet J, Mantzouranis E, Cruz A, Ait-Khaled N, Baena-Cagnani C, Bleecker E . Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol. 2010; 126(5):926-38. DOI: 10.1016/j.jaci.2010.07.019. View

15.

Bousquet J, Kiley J, Bateman E, Viegi G, Cruz A, Khaltaev N . Prioritised research agenda for prevention and control of chronic respiratory diseases. Eur Respir J. 2010; 36(5):995-1001. DOI: 10.1183/09031936.00012610. View

16.

Haahtela T, Valovirta E, Bousquet J, Makela M . The Finnish Allergy Programme 2008-2018 works. Eur Respir J. 2017; 49(6). DOI: 10.1183/13993003.00470-2017. View

17.

Dooris M . Healthy settings: challenges to generating evidence of effectiveness. Health Promot Int. 2005; 21(1):55-65. DOI: 10.1093/heapro/dai030. View

18.

Samolinski B, Fronczak A, Kuna P, Akdis C, Anto J, Bialoszewski A . Prevention and control of childhood asthma and allergy in the EU from the public health point of view: Polish Presidency of the European Union. Allergy. 2012; 67(6):726-31. PMC: 3504073. DOI: 10.1111/j.1398-9995.2012.02822.x. View

19.

Blanc P, Trupin L, Eisner M, Earnest G, Katz P, Israel L . The work impact of asthma and rhinitis: findings from a population-based survey. J Clin Epidemiol. 2001; 54(6):610-8. DOI: 10.1016/s0895-4356(00)00349-8. View

20.

Selroos O, Kupczyk M, Kuna P, Lacwik P, Bousquet J, Brennan D . National and regional asthma programmes in Europe. Eur Respir Rev. 2015; 24(137):474-83. PMC: 9487682. DOI: 10.1183/16000617.00008114. View